Compare · EVMN vs NVO
EVMN vs NVO
Side-by-side comparison of Evommune Inc. (EVMN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 251.9x EVMN ($727.2M).
- Over the past year, EVMN is up 3.7% and NVO is down 44.1% - EVMN leads by 47.8 points.
- EVMN has been more active in the news (13 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for EVMN).
- Company
- Evommune Inc.
- Novo Nordisk A/S
- Price
- $20.50+1.74%
- $42.19+2.89%
- Market cap
- $727.2M
- $183.15B
- 1M return
- -10.09%
- -8.44%
- 1Y return
- +3.69%
- -44.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 13
- 8
- Recent ratings
- 10
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EVMN
- SEC Form 4 filed by Director Mcgraw Benjamin F Iii
- SEC Form 4 filed by Director Kirsch Arthur S
- Director Cohen David E sold $123,094 worth of shares (6,056 units at $20.33) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 17,609 units (SEC Form 4)
- Chief Scientific Officer Patel Jeegar Pravinkumar sold $379,462 worth of shares (16,687 units at $22.74) as part of a pre-agreed trading plan and exercised 13,512 shares at a strike of $3.84, decreasing direct ownership by 6% to 46,403 units (SEC Form 4)
- President & CEO Pena Luis C. sold $381,736 worth of shares (16,787 units at $22.74) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 637,896 units (SEC Form 4)
- SEC Form 144 filed by Evommune Inc.
- SEC Form 424B3 filed by Evommune Inc.
- Evommune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Business & Legal Officer Moss Gregory S. exercised 14,223 shares at a strike of $1.71 and sold $324,711 worth of shares (14,223 units at $22.83) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Carver Kyle exercised 15,000 shares at a strike of $2.99 and sold $415,117 worth of shares (18,175 units at $22.84) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,335 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care